IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$75.97-0.43 (-0.56%)
01:30 PM07:45 PM
News · 26 weeks121+38%
2025-12-282026-06-21
Mix4090d
- Insider17(43%)
- Other10(25%)
- SEC Filings8(20%)
- Analyst3(8%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDEREVP, Chief Development Officer Kordasiewicz Holly B. exercised 60,846 shares at a strike of $53.97 and sold $4,466,428 worth of shares (60,846 units at $73.41) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Berthelsen Spencer R exercised 8,000 shares at a strike of $24.42 and sold $587,920 worth of shares (8,000 units at $73.49) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- INSIDERSEC Form 4 filed by Director Reikes Peter N4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Hantson Ludwig4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reikes Peter N3 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hantson Ludwig3 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis announces appointment of Ludwig Hantson, Ph.D. to Board of DirectorsIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately."We are pleased to welcome Dr. Hantson to the board," said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. "Ludwig's biopharma executive leadership experience will be especially meaningful as Ionis prepares for a steady cadence of new commercial launches, including two additional independent launches this year, while continuing to scale its operations as a fully integrated biotechnology company."Dr. Hantson has more than 30 years of leadership experience at biopharmac
- PRIonis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congressesIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans (June 5-8), the National Lipid Association (NLA) Scientific Sessions in Chicago (June 11-14) and ENDO 2026, the Endocrine Society's annual meeting in Chicago (June 13-16). "People living with sHTG are at risk of acute pancreatitis, a debilitatingly painful complication that can potentially be life-threateni
- INSIDERDirector Berthelsen Spencer R exercised 8,000 shares at a strike of $24.42 and sold $605,360 worth of shares (8,000 units at $75.67) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis – – A loss in surface antigen is associated with a significant reduction in risk of liver cancer – – Over 240 million people worldwide live with chronic hepatitis B – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB
- ANALYSTCitigroup initiated coverage on Ionis Pharma with a new price targetCitigroup initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $115.00
- INSIDERChief Executive Officer Monia Brett P exercised 4,536 shares at a strike of $32.60 and sold $356,012 worth of shares (4,536 units at $78.49) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study - - Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose - - The safety and tolerability profile of diranersen was generally consistent with the Phase 1b study - - Data will be presented at the Alzheimer's Association International Conference (AAIC) 2026
- INSIDERDirector Loscalzo Joseph exercised 77,289 shares at a strike of $48.74 and sold $5,801,226 worth of shares (77,289 units at $75.06) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERDirector Klein Joseph Iii exercised 10,111 shares at a strike of $47.11 and sold $743,238 worth of shares (10,111 units at $73.51) as part of a pre-agreed trading plan (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis to host 2026 virtual Annual Meeting of StockholdersIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2026, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2026. Stockholders of record will receive an official proxy card or notice from their brokerage firm. Each proxy card/notice contains a 16-digit cont
- PRIonis to present at upcoming investor conferencesIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time. About Ionis Pharm
- INSIDEREVP, Chief Business Officer Baroldi Joseph sold $116,727 worth of shares (1,626 units at $71.79) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 44,909 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECSEC Form 10-Q filed by Ionis Pharmaceuticals Inc.10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis reports first quarter 2026 financial results and highlights progress on key programs- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to >$3B for sHTG – - Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis' first independent launch from leading neurology pipeline – - Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the first quarter ended March 31, 2026. "Ionis' stro
- PRIonis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to Fast Track Designation, recognizing potential for substantial improvement over existing treatments – – Chronic hepatitis B is a leading cause of liver cancer globally – – PDUFA Date of October 26, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of adu
IONS FAQ
6 questionsWhat does Ionis Pharmaceuticals Inc. do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases...Where does IONS stock trade?
Ionis Pharmaceuticals Inc. (IONS) is listed on NASDAQ.What sector and industry is IONS in?
Ionis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IONS?
Ionis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-05-19.What companies are similar to IONS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IONS side-by-side with any of them on Quantisnow.How can I track IONS on Quantisnow?
Quantisnow aggregates Ionis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IONS to receive live email and push alerts on every new disclosure.